SpyGlass Pharma Inc(SGP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 7:30 PM ET (Korea 9/15 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 58.24% | Shs Outstand | 33.5M | Perf Week | -0.97% |
| Market Cap | 0.96B | Forward P/E | - | EPS next Y | -12.63% | Insider Trans | - | Shs Float | 14.0M | Perf Month | 13.87% |
| Enterprise Value | 0.73B | PEG | - | EPS next Q | -0.62 | Inst Own | 40.59% | Short Float | 7.85% | Perf Quarter | 55.42% |
| Income | - | P/S | - | EPS this Y | 86.1% | Inst Trans | 2.91% | Short Ratio | 9.18 | Perf Half Y | 7.95% |
| Sales | - | P/B | 4.13 | EPS next 5Y | 44.6% | ROA | - | Short Interest | 1.10M | Perf YTD | 19.42% |
| Book/sh | 6.95 | P/C | 4.09 | EPS past 3/5Y | -69.04% - | ROE | - | 52W High | -11.65% ($32.44) | Perf Year | - |
| Cash/sh | 7 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 68% ($17.06) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.55% 5.01% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 25.06 | EPS Q/Q | 84.99% | Profit Margin | - | RSI (14) | 64.99 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 25.06 | Sales Q/Q | - | SMA20 | 5.46% ($27.18) | Beta | - | Target Price | $44 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | 18.9% ($24.1) | Rel Volume | 1.09 | Prev Close | $27.52 |
| Employees | 65 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -14.7% - | SMA200 | 20.74% ($23.74) | Avg Volume(3M) | 0.12M | Price | $28.66 |
| IPO | 2026/2/6 | Option/Short | No/Yes | Trades | 2681 | Volume | 130,173 | Change | 4.14% |
Company
SGP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
👁️ SpyGlass Pharma (SGP) is a U.S. biotech company developing long-acting drug delivery platforms targeting ophthalmic diseases. Its lead candidate incorporates bimatoprost into an intraocular lens implanted during cataract surgery, enabling long-term drug delivery for patients with glaucoma and elevated intraocular pressure. The company has achieved meaningful results in clinical-stage development and is pursuing a differentiated approach in the field of ophthalmic drug delivery.
Over the past 1 year, on the higher side
12% below its 1-year high.
SGP makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 40.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IWM 0.00%
IWN 0.00%
IWO 0.00%
SCHA 0.00%It ranks #4 in the industry
Based on market cap of $959M.
SGP $959M PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is SGP?
SGP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SGP?
The market cap of SGP is approximately $959M, ranking 2,672 within its sector.
What is the 52-week high and low for SGP?
SGP has recorded a 52-week high of $32.44 and a low of $17.06.
